Companies / Bicara Therapeutics Inc.
Bicara Therapeutics Inc.
Nasdaq: BCAXCIK 2023658BOSTON, MA
Financials
Ownership
66.2M shares outstanding · as of Aug 6, 2026
Ownership
| Insiders | 8.08% | 5,344,092 |
| 10%+ / strategic | 14.11% | 9,333,818 |
| Institutions | 68.61% | 45,400,517 |
| Public float | 9.21% | 6,094,507 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 11
View all →| Insider | % of shares | Shares |
|---|---|---|
RA Capital Management, L.P.Director · 10% owner | 6.96% | 4,603,418 |
Mazumdar ClaireCEOChief Executive Officer · Director | 0.51% | 339,392 |
Cohlhepp RyanPresident and COO · Director | 0.30% | 200,641 |
Hyep IvanChief Financial Officer | 0.22% | 145,355 |
Raben DavidChief Medical Officer | 0.08% | 55,286 |
Kolchinsky PeterDirector · 10% owner | — | — |
Meisner LaraChief Legal Officer | — | — |
Powell MichaelDirector | — | — |
RA Capital Healthcare Fund LPDirector · 10% owner | — | — |
RA Capital Nexus Fund III, L.P.Director | — | — |
Institutional holders 147
View all →| Holder | Value | % of shares |
|---|---|---|
| $144.32M | 10.97% | |
| $114.25M | 5.82% | |
| $87.80M | 7.88% | |
| $66.35M | 5.05% | |
| $60.83M | 3.10% | |
| $60.17M | 5.40% | |
| $56.33M | 5.06% | |
| $53.36M | 4.79% | |
| $50.67M | 4.55% | |
| $43.99M | 3.95% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | RA Capital Management, L.P. Director | Buy | Common Stock | $4.80M | +300K +6.97% | 4,603,418 6.96% of shares | high |
| Mar 9, 2026 | Mazumdar Claire CEO | Sell | Common Stock | $704.7K | -37K -9.77% | 339,392 0.51% of shares | medium |
| Mar 4, 2026 | Raben David Executive | Sell | Common Stock | $301.9K | -16K -22.77% | 55,286 0.08% of shares | medium |
| Mar 3, 2026 | Hyep Ivan Executive | Sell | Common Stock | $246.9K | -14K -8.53% | 145,355 0.22% of shares | medium |
| Mar 3, 2026 | Cohlhepp Ryan Executive | Sell | Common Stock | $234.2K | -13K -5.79% | 209,641 0.32% of shares | medium |
| Mar 23, 2026 | Hyep Ivan Executive | Sell | Common Stock | $170.3K | -9K -5.95% | 145,355 0.22% of shares | medium |
| Mar 16, 2026 | Cohlhepp Ryan Executive | Sell | Common Stock | $157.3K | -8K -3.75% | 205,141 0.31% of shares | medium |
| Mar 9, 2026 | Mazumdar Claire CEO | Exercise | Common Stock | $139.3K | +37K +10.83% | 376,158 0.57% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Deep Track Capital, LP | Passive13G | — |
| T. Rowe Price Investment Management, Inc. | Passive13G | — |
| Vestal Point Capital, LP | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| Janus Henderson Group PLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| BCAX | — | 055477103 |